Bryce Vissel
Affiliations: | 2003-2008 | Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia |
Google:
"Bryce Vissel"Mean distance: 53433
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Konen LM, Wright AL, Royle GA, et al. (2020) A new mouse line with reduced GluA2 Q/R site RNA editing exhibits loss of dendritic spines, hippocampal CA1-neuron loss, learning and memory impairments and NMDA receptor-independent seizure vulnerability. Molecular Brain. 13: 27 |
| Stayte S, Laloli KJ, Rentsch P, et al. (2019) The kainate receptor antagonist UBP310 but not single deletion of GluK1, GluK2, or GluK3 subunits, inhibits MPTP-induced degeneration in the mouse midbrain. Experimental Neurology. 113062 |
| Rentsch P, Stayte S, Morris GP, et al. (2019) Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia. Bmc Neuroscience. 20: 5 |
| Clark IA, Vissel B. (2018) Therapeutic implications of how TNF links APOE, P-tau, α-synuclein, β-amyloid, and insulin resistance in neurodegenerative diseases. British Journal of Pharmacology |
| Clark IA, Vissel B. (2017) The meteorology of cytokine storms, and the clinical usefulness of this knowledge. Seminars in Immunopathology |
| Stayte S, Rentsch P, Tröscher AR, et al. (2017) Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations and Loss of Dopamine Neurons in the Mouse Midbrain In Vivo. Plos One. 12: e0167211 |
| Clark IA, Vissel B. (2016) Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. Journal of Neuroinflammation. 13: 236 |
| Clark IA, Vissel B. (2015) A Neurologist's Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in Disease. Neural Plasticity. 2015: 358263 |
| Stayte S, Rentsch P, Li KM, et al. (2015) Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease. Plos One. 10: e0124325 |
| Stayte S, Vissel B. (2014) Advances in non-dopaminergic treatments for Parkinson's disease. Frontiers in Neuroscience. 8: 113 |